Currently out of the existing stock ratings of Dennis Ding, 29 are a BUY (64.44%), 16 are a HOLD (35.56%).
Analyst Dennis Ding, currently employed at JEFFERIES, has had 65% of price targets met with an average potential upside of 24.1%, reached in 179 days on average.
Dennis Ding has documented 89 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ROIV, Roivant Sciences Ltd at 07-Sep-2026.
Analyst best performing recommendations are on MIST (MILESTONE PHARMACEUTICALS).
The best stock recommendation documented was for NGM (NGM BIOPHARMACEUTICALS) on 10/17/2022. The price target of $4 was fulfilled within 3 days with a profit of $0.59 (17.3%), with a performance score of 57.67.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 15-Sep-2020
$5
$0.91 (22.25%)
$5
8 months 14 days ago
(04-Mar-2026)
10/15 (66.67%)
$0.25 (5.26%)
442
Buy Since 05-Nov-2021
$5
$5
1 years 7 months 18 days ago
(31-Mar-2025)
4/9 (44.44%)
$1.51 (43.27%)
420
Buy Since 17-Dec-2020
$5
$5
1 years 9 months 28 days ago
(21-Jan-2025)
5/19 (26.32%)
$1.79 (55.76%)
671
Hold Since 29-Dec-2021
$5
$4
4 years 9 months 16 days ago
(02-Feb-2022)
2/2 (100%)
$2.11 (73.01%)
1298
Buy Since 05-Mar-2020
$7
$7
5 years 4 months 21 days ago
(28-Jun-2021)
0/6 (0%)
$3.63 (107.72%)
Which stock is Dennis Ding most bullish on?
Which stock is Dennis Ding most reserved on?
What Year was the first public recommendation made by Dennis Ding?